Results 111 to 120 of about 3,811,568 (245)

Artificial intelligence empowers targeted protein degradation: Core technological innovations, multi‐scenario applications, and translational prospects

Smart Molecules, EarlyView.
AI is transforming TPD by improving the design, prediction, and optimization of degraders such as PROTACs, molecular glues, and LYTACs. This review summarizes key AI‐driven advances, highlights applications across drug discovery stages, and discusses remaining challenges and future directions for accelerating the development of therapies against ...
Shuanglin Qin, Rui Peng, Guangshuai Zhang, Si Yan, Jin Xiao, Zishu Liu, Ziyu Tan, Qingqing Xie, Shangjie Li, Wei Luo, Xiaohe Xiao   +10 more
wiley   +1 more source

Recent progress on the development of hydrogel‐based microneedles for transdermal drug delivery

VIEW, EarlyView.
This study provides a comprehensive and up‐to‐date analysis of recent progress in HMN technology, covering fundamental transdermal delivery mechanisms and design principles, biomaterials used in HMN fabrication, drug loading and release strategies, and emerging therapeutic applications.
Mohammad Muhtasim Ittisaf, Salman Farsi Taharat, Md. Sadek Miah, Hasan Tasnim Salehin, M. Azam Ali, Shoeb Ahmed   +5 more
wiley   +1 more source

Comparative effectiveness of apalutamide‐, abiraterone‐, and enzalutamide‐based doublets in mHSPC

BJU International, EarlyView.
Background and Objective Treatment of metastatic hormone‐sensitive prostate cancer (mHSPC) has evolved from androgen‐deprivation therapy (ADT) alone to combination therapy with androgen receptor pathway inhibitors. Although apalutamide (APA), abiraterone (ABI), and enzalutamide (ENZA) improve outcomes when added to ADT, direct comparative trials ...
Anikó Katalin Valikovics, Dániel Bacsó, Nadeen Samaien, Isabel Pinto Amorim das Virgens, Mahmoud Obeidat, Gergely Bánfi, Boris Hadaschik, Péter Hegyi, Péter Nyirády, Tibor Szarvas   +9 more
wiley   +1 more source

Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities

Research and Reports in Urology, 2023
Eun-mi Yu,1 Min Woo Hwang,2 Jeanny B Aragon-Ching1 1GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA, USA; 2Department of Internal Medicine, Inova Fairfax Hospital, Fairfax, VA, USACorrespondence: Jeanny B Aragon-Ching, Clinical Program ...
Yu EM, Hwang MW, Aragon-Ching JB
doaj  

Population Pharmacokinetics of Cabozantinib: Updated Analyses Including Data in Combination With Atezolizumab in Patients With Castration‐Resistant Prostate Cancer and Other Tumor Types [PDF]

Clin Transl Sci
ABSTRACT Cabozantinib is a small‐molecule tyrosine kinase inhibitor approved for the treatment of various locally advanced or metastatic solid tumors. The phase 1b COSMIC‐021 study evaluated cabozantinib as a monotherapy or in combination with atezolizumab in patients with advanced solid tumors, including castration‐resistant prostate cancer (CRPC ...
Williams J, Li H, Othman A.
europepmc   +2 more sources

Castration Resistant Prostate Cancer: Role of Chemotherapy

, 2016
The last decade brought many new treatment options that changed the treatment algorithms for metastatic castrate-resistant prostate cancer (mCRPC). One of the most challenging tasks today is the optimal sequencing of agents since timing and patient ...
Marijo Bilusic, Bilusic, Marijo
core   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Role of Signaling Transduction Pathways in Development of Castration-Resistant Prostate Cancer

Prostate Cancer, 2011
Almost all patients who succumb to prostate cancer die of metastatic castration-resistant disease. Although docetaxel is the standard treatment for this disease and is associated with modest prolongation of survival, there is an urgent need for novel ...
Takahiro Inoue, Osamu Ogawa
doaj   +1 more source

Extracellular vesicles in pharmacology: Innovations in drug delivery and therapeutic applications in cancer

British Journal of Pharmacology, EarlyView.
Extracellular vesicles (EVs) are a diverse population of membrane nanoparticles secreted by nearly all cell types, playing a key role in intercellular communication by transferring bioactive macromolecular cargo. In cancer, EVs shape both the local tumour microenvironment and distant premetastatic niches.
Evangelia Pantazaka, Georgios Sivvas, Evangelia Papadimitriou, Constantinos M. Mikelis   +3 more
wiley   +1 more source

PROCA11 early activation fuels prostate cancer neuroendocrine traits by regulating cell survival and migration

iScience
Summary: Tumor plasticity drives the emergence of castration-resistant and neuroendocrine prostate cancer following androgen-deprivation therapy (ADT).
Rocco Cipolla, Marc Gabriel, Ugo Szachnowski, Zhimin Wang, Martina Romani, Giorgia Ianese Regin, Micaela Piemontese, Virginie Firlej, Marina Pinskaya, Antonin Morillon   +9 more
doaj   +1 more source